Camlin Tierney

3.6k total citations · 1 hit paper
60 papers, 2.4k citations indexed

About

Camlin Tierney is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Camlin Tierney has authored 60 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Infectious Diseases, 27 papers in Virology and 17 papers in Emergency Medicine. Recurrent topics in Camlin Tierney's work include HIV/AIDS drug development and treatment (39 papers), HIV/AIDS Research and Interventions (34 papers) and HIV Research and Treatment (27 papers). Camlin Tierney is often cited by papers focused on HIV/AIDS drug development and treatment (39 papers), HIV/AIDS Research and Interventions (34 papers) and HIV Research and Treatment (27 papers). Camlin Tierney collaborates with scholars based in United States, Zimbabwe and South Africa. Camlin Tierney's co-authors include Eric S. Daar, Paul E. Sax, Belinda Ha, Nasreen C. Jahed, Roy M. Gulick, Grace A. McComsey, Douglas Kitch, Kathleen Melbourne, Laurie Myers and Heather J. Ribaudo and has published in prestigious journals such as New England Journal of Medicine, Annals of Internal Medicine and PLoS ONE.

In The Last Decade

Camlin Tierney

58 papers receiving 2.3k citations

Hit Papers

Bone Mineral Density and Fractures in Antiretroviral-Naiv... 2011 2026 2016 2021 2011 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202
    2011 381 citations Grace A. McComsey, Douglas Kitch et al. The Journal of Infectious Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Camlin Tierney United States 21 1.7k 1.2k 899 383 200 60 2.4k
Heather J. Ribaudo United States 34 3.2k 1.9× 2.4k 2.0× 1.6k 1.8× 658 1.7× 366 1.8× 112 4.4k
Daniel Podzamczer Spain 29 3.3k 1.9× 2.4k 2.1× 1.5k 1.6× 726 1.9× 138 0.7× 144 4.0k
Ana Milinkovic Spain 25 1.4k 0.8× 771 0.7× 890 1.0× 818 2.1× 101 0.5× 70 2.3k
Mark S. Shaefer United States 24 1.5k 0.9× 1.1k 0.9× 438 0.5× 419 1.1× 222 1.1× 79 2.4k
Xuelian Wei United States 17 1.6k 1.0× 1.0k 0.9× 886 1.0× 254 0.7× 116 0.6× 33 2.0k
Laura Smeaton United States 28 2.1k 1.2× 1.5k 1.3× 636 0.7× 722 1.9× 167 0.8× 75 2.8k
Achim Schwenk United Kingdom 25 783 0.5× 344 0.3× 433 0.5× 474 1.2× 68 0.3× 55 1.9k
Sherene Min United States 24 3.1k 1.8× 2.3k 2.0× 654 0.7× 556 1.5× 223 1.1× 46 3.3k
Kitty Yale United States 16 1.2k 0.7× 837 0.7× 389 0.4× 646 1.7× 125 0.6× 21 1.9k
Lene Ryom Denmark 26 1.8k 1.1× 791 0.7× 1.8k 2.0× 855 2.2× 74 0.4× 74 2.9k

Countries citing papers authored by Camlin Tierney

Since Specialization
Citations

This map shows the geographic impact of Camlin Tierney's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Camlin Tierney with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Camlin Tierney more than expected).

Fields of papers citing papers by Camlin Tierney

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Camlin Tierney. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Camlin Tierney. The network helps show where Camlin Tierney may publish in the future.

Co-authorship network of co-authors of Camlin Tierney

This figure shows the co-authorship network connecting the top 25 collaborators of Camlin Tierney. A scholar is included among the top collaborators of Camlin Tierney based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Camlin Tierney. Camlin Tierney is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bhattacharya, Debika, Camlin Tierney, Flavia Matovu Kiweewa, et al.. (2023). Comparison of Antiretroviral Therapies in Pregnant Women Living With Human Immunodeficiency Virus and Hepatitis B Virus. Obstetrics and Gynecology. 142(3). 613–624.
2.
Tierney, Camlin, Deborah Persaud, Jennifer Jao, et al.. (2022). Infants Receiving Very Early Antiretroviral Therapy Have High CD4 Counts in the First Year of Life. Clinical Infectious Diseases. 76(3). e744–e747. 2 indexed citations
3.
Brummel, Sean S., Ed Mills, Camlin Tierney, et al.. (2022). Clinical and population‐based study design considerations to accelerate the investigation of new antiretrovirals during pregnancy. Journal of the International AIDS Society. 25(S2). e25917–e25917. 8 indexed citations
4.
Mollan, Katie R., Brian W. Pence, Jessie K. Edwards, et al.. (2021). Transportability From Randomized Trials to Clinical Care: On Initial HIV Treatment With Efavirenz and Suicidal Thoughts or Behaviors. American Journal of Epidemiology. 190(10). 2075–2084. 9 indexed citations
5.
Mollan, Katie R., Camlin Tierney, Jacklyn N. Hellwege, et al.. (2017). Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants. The Journal of Infectious Diseases. 216(5). 554–564. 25 indexed citations
6.
Venuto, Charles S., Qing Ma, Eric S. Daar, et al.. (2017). Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants. Therapeutic Drug Monitoring. 39(6). 596–603. 10 indexed citations
7.
Dumond, Julie B., Joseph Rigdon, Katie R. Mollan, et al.. (2015). Brief Report. JAIDS Journal of Acquired Immune Deficiency Syndromes. 70(5). 510–514. 5 indexed citations
8.
Longenecker, Chris T., Douglas Kitch, Paul E. Sax, et al.. (2015). Reductions in Plasma Cystatin C After Initiation of Antiretroviral Therapy Are Associated With Reductions in Inflammation. JAIDS Journal of Acquired Immune Deficiency Syndromes. 69(2). 168–177. 10 indexed citations
9.
Wyatt, Christina, Douglas Kitch, Samir K. Gupta, et al.. (2014). Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine. PMC. 1 indexed citations
10.
McComsey, Grace A., Douglas Kitch, Paul E. Sax, et al.. (2013). Associations of Inflammatory Markers With AIDS and Non-AIDS Clinical Events After Initiation of Antiretroviral Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes. 65(2). 167–174. 52 indexed citations
11.
Erlandson, Kristine M., Douglas Kitch, Camlin Tierney, et al.. (2013). Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density. AIDS. 27(13). 2069–2079. 37 indexed citations
12.
Sha, Beverly E., Camlin Tierney, Susan E. Cohn, et al.. (2011). Postpartum Viral Load Rebound in HIV-1–Infected Women Treated with Highly Active Antiretroviral Therapy: AIDS Clinical Trials Group Protocol A5150. HIV Clinical Trials. 12(1). 9–23. 31 indexed citations
13.
McComsey, Grace A., Douglas Kitch, Eric S. Daar, et al.. (2011). Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202. The Journal of Infectious Diseases. 203(12). 1791–1801. 381 indexed citations breakdown →
14.
15.
Sax, Paul E., Camlin Tierney, Ann C. Collier, et al.. (2011). Abacavir/Lamivudine Versus Tenofovir DF/Emtricitabine as Part of Combination Regimens for Initial Treatment of HIV: Final Results. The Journal of Infectious Diseases. 204(8). 1191–1201. 130 indexed citations
16.
Collier, Ann C., Camlin Tierney, Gerald Downey, et al.. (2008). Randomized Study of Dual Versus Single Ritonavir-Enhanced Protease Inhibitors for Protease Inhibitor-Experienced Patients with HIV. HIV Clinical Trials. 9(2). 91–102. 8 indexed citations
17.
Kashuba, Angela D. M., Camlin Tierney, Gerald Downey, et al.. (2005). Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results. AIDS. 19(2). 145–152. 48 indexed citations
18.
Pollard, Richard B., Camlin Tierney, Diane V. Havlir, et al.. (2002). A Phase II Randomized Study of the Virologic and Immunologic Effect of Zidovudine + Stavudine versus Stavudine Alone and Zidovudine + Lamivudine in Patients with >300 CD4 Cells Who Were Antiretroviral Naive (ACTG 298). AIDS Research and Human Retroviruses. 18(10). 699–704. 7 indexed citations
19.
Lathey, Janet L., Camlin Tierney, Richard T. D’Aquila, et al.. (2001). Associations of CCR5, CCR2, and Stromal Cell–Derived Factor 1 Genotypes with Human Immunodeficiency Virus Disease Progression in Patients Receiving Nucleoside Therapy. The Journal of Infectious Diseases. 184(11). 1402–1411. 23 indexed citations
20.
Tierney, Camlin & Barbara McKnight. (1993). Power of Affected Sibling Method Tests for Linkage. Human Heredity. 43(5). 276–287. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Heather J. Ribaudo Breakdown of academic impact, for papers by Daniel Podzamczer Breakdown of academic impact, for papers by Ana Milinkovic Breakdown of academic impact, for papers by Mark S. Shaefer Breakdown of academic impact, for papers by Xuelian Wei Breakdown of academic impact, for papers by Laura Smeaton Breakdown of academic impact, for papers by Achim Schwenk Breakdown of academic impact, for papers by Sherene Min Breakdown of academic impact, for papers by Kitty Yale Breakdown of academic impact, for papers by Lene Ryom
Rankless by CCL
2026